Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have been given a consensus rating of “Hold” by the nine analysts that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $28.75.
Several analysts have recently issued reports on LXRX shares. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Wedbush reiterated an “ourperform” rating and set a $39.00 target price on shares of Lexicon Pharmaceuticals in a research report on Monday. BidaskClub downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Finally, ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th.
Shares of Lexicon Pharmaceuticals (LXRX) opened at 14.51 on Friday. Lexicon Pharmaceuticals has a 12 month low of $13.41 and a 12 month high of $19.62. The company’s 50 day moving average price is $16.24 and its 200-day moving average price is $15.41. The firm’s market capitalization is $1.53 billion.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The business had revenue of $12 million for the quarter, compared to the consensus estimate of $18.34 million. During the same period in the prior year, the business earned ($0.37) earnings per share. The business’s revenue was down 40.3% on a year-over-year basis. On average, equities analysts predict that Lexicon Pharmaceuticals will post ($1.45) earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the company. C WorldWide Group Holding A S increased its position in Lexicon Pharmaceuticals by 2.5% in the first quarter. C WorldWide Group Holding A S now owns 11,677 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 280 shares during the period. 361 Capital LLC acquired a new position in Lexicon Pharmaceuticals during the first quarter valued at $186,000. First Mercantile Trust Co. increased its position in Lexicon Pharmaceuticals by 11.2% in the second quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 1,227 shares during the period. Cim Investment Mangement Inc. acquired a new position in Lexicon Pharmaceuticals during the second quarter valued at $262,000. Finally, Pacad Investment Ltd. acquired a new position in Lexicon Pharmaceuticals during the second quarter valued at $265,000.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.